8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 25, 2017)

Filed January 25, 2017For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on January 25, 2017, to report on events impacting its financial reporting following the completion of its acquisition of St. Jude Medical, Inc. on January 4, 2017. This filing is significant as it outlines the new segment structure for Abbott's cardiovascular and neuromodulation (ACN) business, which now incorporates St. Jude Medical's operations. Investors should note the reclassification of products into specific categories within ACN, which will be crucial for understanding future sales performance and segment growth. The company has provided details on how its ACN sales will be reported, divided into "Rhythm Management and Heart Failure," "Cardiovascular and Structural Heart," and "Neuromodulation." The filing also directs investors to Exhibit 99.1 for comparable revenue data by product category for the full year 2016 and quarterly periods within 2016. This exhibit is essential for investors to establish a baseline and assess the initial performance of the combined entity in the upcoming reporting periods.

Key Highlights

  • 1Abbott Laboratories completed the acquisition of St. Jude Medical, Inc. on January 4, 2017.
  • 2The filing details the revised reporting structure for Abbott's Cardiovascular and Neuromodulation (ACN) business.
  • 3The ACN business will now include former St. Jude Medical product lines.
  • 4New reporting categories within ACN are: Rhythm Management and Heart Failure, Cardiovascular and Structural Heart, and Neuromodulation.
  • 5Exhibit 99.1 provides comparable revenue data for these product categories for 2016.
  • 6This information is crucial for understanding the financial performance of the integrated St. Jude Medical business starting in Q1 2017.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors about the changes in Abbott Laboratories' financial reporting structure following the acquisition of St. Jude Medical, Inc. It details how the combined cardiovascular and neuromodulation business will be segmented and reported going forward.

The acquisition of St. Jude Medical, Inc. was completed on January 4, 2017.

Exhibit 99.1, which is furnished as part of this 8-K filing, provides comparable revenue data for each product category within the Cardiovascular and Neuromodulation segment for the full year 2016 and for each quarter of 2016.

The ACN business will be reported in three main categories: Rhythm Management and Heart Failure, Cardiovascular and Structural Heart, and Neuromodulation. These categories encompass a broad range of medical devices from both Abbott and the acquired St. Jude Medical operations.